Taking AIM at Breast Cancer: Targeting Adiposity and Inflammation With Movement to Improve Prognosis in Breast Cancer Survivors
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 试验地点
- 2
- 主要终点
- Reduction of adipose tissue inflammation assessed by measuring M1 and M2 adipose tissue macrophages, crown-like structures, and adipose tissue secretion levels of inflammatory cytokines secreted
研究概览
简要总结
This randomized phase II trial studies how well exercise intervention works in targeting adiposity and inflammation with movement to improve prognosis in stage I-III breast cancer survivors. Different types of exercise may reduce inflammation in fat tissue and minimize the risk of cancer recurrence related to being overweight or obese.
详细描述
PRIMARY OBJECTIVES:
I. To determine the effects of a 4-month circuit, interval-based aerobic and resistance exercise (CARE) intervention on obesity-associated chronic inflammation.
SECONDARY OBJECTIVES:
I. To determine the effects of a 4-month CARE intervention on sarcopenic obesity.
TERTIARY OBJECTIVES:
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Supportive Care
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Postmenopausal (at time of diagnosis; including artificial menopause induced by previous hysterectomy) women newly diagnosed (stage I-III) breast cancer low grade disease positive for estrogen and progesterone receptors
- •Are centrally obese with the following criteria (determined by study team at eligibility screening): body mass index (BMI) > 30 kg/m^2 (calculated using height and weight; an upper limit BMI will not be set; we will rely on obtaining physicians' clearance to assess full eligibility) or body fat > 30% (estimated by bioelectrical impedance), and waist circumference > 35 inches (in)
- •Have undergone a lumpectomy or mastectomy
- •Have received and completed neoadjuvant or adjuvant chemotherapy and/or radiation therapy within the past 12 months
- •Speak English or Spanish
- •Is in breast cancer remission with no detectable disease present
- •Able to initiate a supervised exercise program (free from any cardiovascular, respiratory or musculoskeletal disease or joint problems that preclude moderate physical activity)
- •Free from history of chronic disease including uncontrolled diabetes, hypertension or thyroid disease
- •Have not experienced a weight reduction >= 10% within past 6 months
- •Currently participate in less than 60 minutes of structured exercise/week
- •No planned reconstructive surgery with flap repair during trial and follow-up period
- •May use adjuvant endocrine therapy if use will be continued for duration of study intervention
- •Does not smoke (no smoking during previous 12 months)
- •Willing to travel to the exercise facility at University of Southern California (USC)
排除标准
- •Patients with metastatic disease
- •Is not centrally obese
- •Has not completed surgery, chemotherapy, or radiation treatment associated with their diagnosis
- •History of any musculoskeletal, cardiorespiratory or neurological diseases that preclude the participation in exercise
- •Participates in more than 60 minutes of structured exercise/week
- •Is planning reconstructive surgery with flap repair during trial and follow-up period
- •Currently smokes
- •Is unable to travel to the exercise facility at USC
结局指标
主要结局
Reduction of adipose tissue inflammation assessed by measuring M1 and M2 adipose tissue macrophages, crown-like structures, and adipose tissue secretion levels of inflammatory cytokines secreted
时间窗: Up to 16 weeks
Analyses for each of the continuous outcomes will involve mixed effects linear regression models, to incorporate the repeatedly measured outcomes. Dependent variables will be the 2- and 4-month measurements of trial outcomes assessed during and at the end of the intervention period. Independent variables will include two indicator variables for treatment group (TARE, attention control) relative to CARE, the baseline value of the outcome, and an indicator variable for measurement time (2-month/4-month). The treatment group effect (2 degrees of freedom) will test for differences in TARE and/or attention control, relative to CARE on the 2- and 4-month outcomes.
次要结局
- Distant DFS defined as events that are either lethal (death from any cause) or a direct threat to patient survival (distant recurrence or second primary invasive cancer)(Up to 8 years)
- Recurrence-free interval defined as events directly attributable to the original breast cancer including invasive ipsilateral breast tumor recurrence; local, regional or distant recurrence; and death from breast cancer(Up to 8 years)
- Overall survival(From randomization to death from any cause, assessed up to 8 years)
- Sarcopenic obesity assessed using dual energy X-ray absorptiometry(Up to 8 months)